October 20, 2020 – Training Opportunities

The Massachusetts General Hospital is pleased to offer a National Cancer Institute-sponsored, 2-year research/training fellowship in nervous system tumors.

October 20, 2020 – Event Highlight

This Symposium will feature the latest advances in melanoma basic science, melanoma formation, computational biology, and clinical management—including “state of the field” updates.

October 06, 2020 – Announcements

We are writing to apprise you of plans for the fall Bridge Project request for applications (RFA). Just as in your own groups, some of the Bridge Project’s processes and timelines have been disrupted by the coronavirus....

October 02, 2020 – ODQ

Trainings and resources for DFCI teams using Adobe Sign for consents and regulatory documents

October 02, 2020 – Office for Human Research Studies

COVID-related modifications trial and consent procedures, "bundling" amendments, translation of previously approved documents, and updates to Outside Interest and Attestation Form

September 15, 2020 – Announcements

Next month marks the inauguration of Dana Farber / Harvard Cancer Center Neuro-Oncology Grand Rounds, a monthly, multidisciplinary, HMS CME conference open to all DF/HCC institutions (BWH, BIDMC, BCH, DFCI, HSPH, HMS,...

September 02, 2020 – ODQ

Both a quick overview and in-depth step-by-step training and guidance are now available!

August 27, 2020 – Cancer Disparities

Thursday, August 6th capped off a 3-day zoomathon of final presentations from a field of 54 CURE and U54 Partnership students that worked with labs across DF/HCC member institutions this summer. Although Karen Burns...

August 18, 2020

Last week DF/HCC officially awarded its first “Grand Challenge” award to Beverly Moy, MD, MPH (MGH) for her project entitled, “Boosting Clinical Trial Accrual Among Underserved Cancer Patients through Partnerships”

August 18, 2020 – Announcements

The Harvard Chan Bioinformatics Core is excited to expand our bioinformatics training program as part of a new collaboration with the Dana-Farber / Harvard Cancer Center (DF/HCC).